Capricor Therapeutics, Inc. reported significant financial challenges in its latest 10-Q filing for the quarter ending September 30, 2025. The company recorded no revenue for the third quarter, a stark contrast to the $2.3 million generated in the same period last year. For the nine months ending September 30, 2025, total revenue was also absent, compared to $11.1 million for the same period in 2024. The lack of revenue is attributed to the completion of milestone payments from its collaboration with Nippon Shinyaku, which were fully recognized in prior periods.
The company's operating expenses surged, with total operating expenses reaching approximately $26.3 million for the third quarter, up from $15.3 million in the same quarter of 2024. Research and development expenses accounted for a significant portion of this increase, totaling $20.4 million, compared to $11.8 million in the prior year. This rise is primarily due to increased personnel costs and expenses related to the ongoing HOPE-3 clinical trial for its lead product candidate, Deramiocel, aimed at treating Duchenne muscular dystrophy (DMD). The net loss for the quarter was approximately $24.6 million, compared to a loss of $12.6 million in the same quarter of 2024.
Capricor's financial position has also deteriorated, with total assets decreasing to $126.4 million as of September 30, 2025, down from $170.5 million at the end of 2024. The company's cash and cash equivalents increased to $19.5 million, while marketable securities dropped to $79.1 million, reflecting a strategic shift in asset management. The accumulated deficit has grown to approximately $274.7 million, raising concerns about the company's ability to sustain operations without additional funding.
In terms of strategic developments, Capricor has been actively pursuing its clinical programs, particularly the HOPE-3 trial, which is critical for the potential approval of Deramiocel. The company has also entered into various commercialization and distribution agreements with Nippon Shinyaku for the U.S. and Japan, which could provide future revenue streams. However, the company has expressed substantial doubt about its ability to continue as a going concern, indicating that it may need to seek additional financing through equity or debt offerings, licensing agreements, or government grants.
Looking ahead, Capricor anticipates that its expenses will continue to rise as it progresses through clinical trials and prepares for potential commercialization. The company is focused on securing additional funding to support its operations and clinical development efforts, particularly for Deramiocel and its exosome platform. The outcome of the ongoing HOPE-3 trial and subsequent regulatory approvals will be pivotal for the company's future financial health and operational viability.
About CAPRICOR THERAPEUTICS, INC.
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company developing cell and exosome-based therapies, primarily focusing on deramiocel, a cell therapy for Duchenne muscular dystrophy (DMD) cardiomyopathy. Its proprietary platforms target muscle degeneration and inflammation through immunomodulatory and regenerative mechanisms. Capricor’s business model centers on advancing clinical development, manufacturing, and partnering for commercialization in key markets including the U.S. and Japan.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.